Zivo Bioscience, Inc 8-K, filed Jun 13, 2024
Zivo Bioscience, Inc. (ZIVO)
About this 8-K
Zivo Bioscience, Inc filed this 8-K on June 13, 2024, reporting on events of June 11, 2024.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter) |
|
| |||
(State or Other Jurisdiction of Incorporation) |
| (Commission File Number) |
| (IRS Employer Identification No.) |
| ||
(Address of Principal Executive Offices) |
| (Zip Code) |
Registrant’s Telephone Number, Including Area Code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
|
| OTCQB | ||
|
| OTC Pink |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.
At the annual meeting of shareholders (the “Annual Meeting”) of Zivo Bioscience, Inc. (the “Company”) held on June 11, 2024, shareholders (i) elected one Class II director to the Company’s Board of Directors to serve a three-year term until the 2027 annual meeting of shareholders, (ii) ratified the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024, and (iii) approved (on an advisory basis) the compensation of the Company’s named executive officers. These proposals are described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 26, 2024.
A total of 1,862,320 shares of the Company’s common stock were present at the meeting in person or by proxy, which represents approximately 66.4% of the shares of common stock outstanding as of the record date for the Annual Meeting.
According to the final vote, the Company’s stockholders approved all three proposals. The final results of the voting are shown below:
Proposal 1—Election of One Class II Director
Nominee |
| Votes For |
|
| Votes Withheld |
|
| Broker Non-Votes |
| |||
Nola E. Masterson |
|
| 1,155,796 |
|
|
| 80,935 |
|
|
| 625,589 |
|
Proposal 2—Ratification of Appointment of Independent Registered Public Accounting Firm
Votes For |
|
| Votes Against |
|
| Votes Abstain |
| |||
| 1,767,252 |
|
|
| 94,680 |
|
|
| 388 |
|
Proposal 3—Approval (on an Advisory Basis) of the Compensation of the Company’s Named Executive Officers
Votes For |
|
| Votes Against |
|
| Votes Abstain |
|
| Broker Non-Votes |
| ||||
| 1,191,591 |
|
|
| 44,773 |
|
|
| 367 |
|
|
| 625,589 |
|
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ZIVO BIOSCIENCE, INC. |
| |
|
| |
By: | /s/ Keith Marchiando |
|
| Keith Marchiando |
|
| Chief Financial Officer |
|
Date: June 13, 2024
3 |